at nucleotide position 143, a guanine at nucleotide position 317, and a cytosine at nucleotide position 316 is indicative of a greater likelihood of having an inflammatory bowel disease in the individual as compared with an individual having one or more of a thymine at nucleotide position 610, a guanine at nucleotide position 514, a cytosine at nucleotide position 218, a cytosine at nucleotide position 425, a guanine at nucleotide position 197, a cytosine at nucleotide position 112, a cytosine at nucleotide position 233, a cytosine at nucleotide position 608, an adenine at nucleotide position 143, a thymine at nucleotide position 317, and a thymine at nucleotide position 316, respectively.

8. (New) A method according to Claim 1, wherein the inflammatory bowel disease is Crohn's disease.

9. (New) A method according to Claim 1, wherein the individual is an individual at risk for development of Crohn's disease.

10. (New) A method for predicting the likelihood that an individual will have an inflammatory bowel disease, comprising the steps of:

a) obtaining a DNA sample from an individual to be assessed; and

b) determining the nucleotide present at one or more of nucleotide positions 610, 514, 218, 425, 197, 112, 233, 608, 143, 317, and 316 relative to the 5' most nucleic acid in SEQ ID NO: 1119, SEQ ID NO: 1124, SEQ ID NO: 1127, SEQ ID NO: 1133, SEQ ID NO: 1142, SEQ ID NO: 1160, SEQ ID NO: 1262, SEQ ID NO: 1294, SEQ ID NO: 1341, SEQ ID NO: 1832, and SEQ ID NO: 1847, respectively,

wherein the presence of one or more of a thymine at nucleotide position 610, a guanine at nucleotide position 514, a cytosine at nucleotide position 218, a cytosine at nucleotide position 425, a guanine at nucleotide position 197, a cytosine at nucleotide position 112, a cytosine at nucleotide position 233, a cytosine at nucleotide position 608, an adenine at nucleotide position 143, a thymine at nucleotide position 317, and a thymine at nucleotide position 316 is indicative of a reduced likelihood of having an inflammatory bowel